Use of Biologics for the Treatment of Inflammatory Conditions of the Pouch: A Systematic Review.

[1]  P. Sagar,et al.  Ileal-anal pouches: A review of its history, indications, and complications , 2019, World journal of gastroenterology.

[2]  S. Vermeire,et al.  Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience , 2019, United European gastroenterology journal.

[3]  N. Hyman,et al.  Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis , 2019, Digestive Diseases and Sciences.

[4]  H. Herfarth,et al.  Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. , 2019, Inflammatory bowel diseases.

[5]  L. A. Christensen,et al.  Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial , 2019, Scandinavian journal of gastroenterology.

[6]  R. Lopez,et al.  Vedolizumab for chronic antibiotic-refractory pouchitis , 2019, Gastroenterology report.

[7]  C. Lees,et al.  P459 Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience , 2019, Journal of Crohn's and Colitis.

[8]  H. Herfarth,et al.  Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. , 2018, Inflammatory bowel diseases.

[9]  B. Shen,et al.  Vedolizumab in the treatment of Crohn’s disease of the pouch , 2018, Gastroenterology report.

[10]  N. Teich,et al.  Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis , 2018, Alimentary pharmacology & therapeutics.

[11]  H. Ikeuchi,et al.  Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis , 2018, Journal of the anus, rectum and colon.

[12]  M. Allez,et al.  Successful Treatment With Ustekinumab for Chronic Refractory Pouchitis. , 2017, Journal of Crohn's & colitis.

[13]  O. Faiz,et al.  Systematic review with meta‐analysis: the management of chronic refractory pouchitis with an evidence‐based treatment algorithm , 2017, Alimentary pharmacology & therapeutics.

[14]  B. Shen,et al.  Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis. , 2017, Inflammatory bowel diseases.

[15]  C. Randall,et al.  Efficacy of Anti-TNF Antibodies in the Treatment of Pouchitis: A Report of 3 Cases: 1737 , 2016 .

[16]  I. Oikonomou,et al.  Single-Center Experience on the Use of Vedolizumab for the Treatment of Inflammatory Conditions of the Ileal Pouch: 2016 ACG Presidential Poster Award: 1729 , 2016 .

[17]  A. Lightner,et al.  Crohn's Disease of the Ileoanal Pouch , 2016, Inflammatory bowel diseases.

[18]  C. Buskens,et al.  Incidence and Severity of Prepouch Ileitis: A Distinct Disease Entity or a Manifestation of Refractory Pouchitis? , 2016, Inflammatory bowel diseases.

[19]  M. Silverberg,et al.  Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.

[20]  H. Ikeuchi,et al.  Clinical Features of Refractory Pouchitis with Penetrating Lesions and the Efficacy of Infliximab Treatment for Patients with Ulcerative Colitis after Restorative Proctocolectomy , 2015, Digestion.

[21]  H. Herfarth,et al.  Use of Biologics in Pouchitis: A Systematic Review , 2015, Journal of clinical gastroenterology.

[22]  E. Dozois,et al.  Long-Term Outcome of IPAA in Patients Presenting with Fulminant Ulcerative Colitis: A Matched Cohort Study , 2015, World Journal of Surgery.

[23]  B. Shen.  Pouchitis: what every gastroenterologist needs to know. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  M. Giakoumis,et al.  Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. , 2013, Journal of Crohn's & colitis.

[25]  Elena A. Manilich,et al.  Ileal Pouch Anal Anastomosis: Analysis of Outcome and Quality of Life in 3707 Patients , 2013, Annals of surgery.

[26]  C. Calabrese,et al.  P.08.2 the Long-Term Clinical Course of Refractory Chronic Pouchitis After Infliximab Therapy , 2013 .

[27]  R. Lopez,et al.  Adalimumab therapy in Crohn's disease of the ileal pouch , 2012, Inflammatory bowel diseases.

[28]  J. Gordillo,et al.  Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series , 2012, European journal of gastroenterology & hepatology.

[29]  P. Rutgeerts,et al.  P262 Patients with refractory pouchitis receiving adalimumab may avoid permanent ileostomy , 2012 .

[30]  J. Gordillo,et al.  Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study , 2011, Inflammatory bowel diseases.

[31]  P. Gionchetti,et al.  OC.01.8 USE OF INFLIXIMAB AND ADALIMUMAB IN REFRACTORY POUCHITIS , 2010 .

[32]  O. Dewit,et al.  Efficacy of infliximab in refractory pouchitis and Crohn's disease‐related complications of the pouch: A Belgian case series , 2010, Inflammatory bowel diseases.

[33]  D. Burke,et al.  An Assessment of Bacterial Dysbiosis in Pouchitis Using Terminal Restriction Fragment Length Polymorphisms of 16S Ribosomal DNA From Pouch Effluent Microbiota , 2009, Diseases of the colon and rectum.

[34]  J. Coffey,et al.  Pathogenesis of and Unifying Hypothesis for Idiopathic Pouchitis , 2009, The American Journal of Gastroenterology.

[35]  J. Goldblum,et al.  Administration of adalimumab in the treatment of Crohn’s disease of the ileal pouch , 2009, Alimentary pharmacology & therapeutics.

[36]  L. Herrinton,et al.  Natural history of severe ulcerative colitis in a community-based health plan. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  F. Remzi,et al.  Risk factors for pouch failure in patients with different phenotypes of Crohn's disease of the pouch , 2008, Inflammatory bowel diseases.

[38]  G. Liguori,et al.  Short‐term treatment with infliximab in chronic refractory pouchitis and ileitis , 2008, Alimentary pharmacology & therapeutics.

[39]  P. Rutgeerts,et al.  Outcome after proctocolectomy with ileal pouch‐anal anastomosis for ulcerative colitis , 2008, Inflammatory bowel diseases.

[40]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[41]  G. D'Haens.  Infliximab for ulcerative colitis: finally some answers. , 2005, Gastroenterology.

[42]  R. Farmer,et al.  Pouch ileitis , 2005, Digestive Diseases and Sciences.

[43]  A. Katz,et al.  Infliximab Therapy in Pediatric Crohn's Pouchitis , 2004, Inflammatory bowel diseases.

[44]  W. Sandborn,et al.  Management of Crohn's disease of the ileoanal pouch with infliximab , 2003, American Journal of Gastroenterology.

[45]  J. Connor,et al.  Modified Pouchitis Disease Activity Index , 2003, Diseases of the colon and rectum.

[46]  R. Caprilli,et al.  Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[47]  P. Lodhavia.  Efficacy of infliximab in the treatment of refractory pouchitis , 2002 .

[48]  R. Thirlby,et al.  Risk Factors and True Incidence of Pouchitis in Patients after Ileal Pouch–Anal Anastomoses , 2000, World Journal of Surgery.

[49]  W. Sandborn.  Pouchitis following heal pouch-anal anastomosis: Definition, pathogenesis, and treatment , 1994 .

[50]  J. Murray,et al.  Long-term results of the ileoanal pouch procedure. , 1993, Archives of surgery.

[51]  P. Munkholm,et al.  Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.